TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)

Vaccine. 2005 Nov 1;23(45):5263-70. doi: 10.1016/j.vaccine.2005.06.024. Epub 2005 Jul 18.


TLR ligands that mimic pathogen associated molecular patterns and activate immune cells via Toll-like receptors (TLRs) are being developed for use in humans as therapy against a variety of diseases as well as vaccine adjuvants. These include imidazoquinoline compounds such as Imiquimod and Resiquimod (R-848) that bind to TLR7 and 8, as well as CpG oligodeoxynucleotides (CpG ODN) that bind to TLR9. This study was aimed at comparing CpG ODN and R-848 for their potential use as vaccine adjuvants and to determine whether there are additive or synergistic effects when they are used together. Using HBsAg as a model antigen in mice, we show CpG ODN to be superior to R-848 for augmenting both humoral and cell mediated immune responses.

Publication types

  • Comparative Study

MeSH terms

  • Adjuvants, Immunologic / pharmacology*
  • Animals
  • Antibody Formation / drug effects
  • Antibody Formation / immunology
  • Cytokines / metabolism
  • Female
  • Hepatitis Antibodies / analysis
  • Hepatitis Antibodies / biosynthesis
  • Hepatitis B Surface Antigens / immunology
  • Imidazoles / pharmacology*
  • Immunity, Cellular / drug effects
  • Immunity, Cellular / immunology
  • Immunization
  • Interferon-gamma / metabolism
  • Mice
  • Mice, Inbred BALB C
  • Oligodeoxyribonucleotides / pharmacology*
  • T-Lymphocytes, Cytotoxic / immunology
  • Toll-Like Receptors / agonists*


  • Adjuvants, Immunologic
  • CPG-oligonucleotide
  • Cytokines
  • Hepatitis Antibodies
  • Hepatitis B Surface Antigens
  • Imidazoles
  • Oligodeoxyribonucleotides
  • Toll-Like Receptors
  • Interferon-gamma
  • resiquimod